<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97302">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01714557</url>
  </required_header>
  <id_info>
    <org_study_id>TZP-HEM-20120608</org_study_id>
    <nct_id>NCT01714557</nct_id>
  </id_info>
  <brief_title>Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Piperacillin/Tazobactam for Prophylaxis in Patients of Neutropenia After Hematopoietic Stem Cell Transplantation - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neutropenia is very common in patients received hematopoietic stem cell transplantation,
      with median duration of about 14 days. Almost all neutropenia will suffer from febrile
      without prophylactic antibiotics. IDSA recommended fluoroquinolones as prophylaxis in
      neutropenia patients of high risks, while in China, major pathogens possess high resistance
      to fluoroquinolones. It is not clear whether prophylaxis is of benefit, nor the appropriate
      prophylaxis regimen.

      The current study will evaluate the three different regimen:

        1. No prophylaxic antibiotic

        2. Piperacillin as prophylaxis for neutropenia patients. Piperacillin has anti-pseudomonas
           activity.

        3. Piperacillin/tazobactam as prophylaxis for neutropenia patients.
           Piperacillin/tazobactam has highest susceptibility rate among common anti-pseudomonas
           antibiotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Swab culture (skin, pharyngeal, nasal, anus) when administered into laminar flow room
           after transplantation.

        2. Randomize the neutropenia patients into 3 groups.

        3. Receive 3 regimen.

        4. Full record of clinical data, including background diseases, previous antibiotics
           within 90 days, febrile or not at the TOC.

        5. For patients developed febrile, imipenem will be prescribed, even if the patient
           received no prophylaxis. At the same time, the follow-up ended.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>febrile rate</measure>
    <time_frame>3 weeks after beginning of prophylaxis</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>In both group, how many patients developed febrile.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiologic efficacy in febrile patients</measure>
    <time_frame>3 weeks after beginning of prophylaxis</time_frame>
    <safety_issue>No</safety_issue>
    <description>The success rate and failure rate will be calculated.
The microbiologic culture is positive at 3 weeks of prophylaxis, showing pathogen sensitive to Piperacillin/tazobactam, the case will be evaluated as breakthrough infection, that means microbiologic failure.
The microbiologic culture is negative at 3 weeks of prophylaxis,, or positive  fungus or non-typical organisms, the case will be evaluated as microbiologic success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery rate from neutropenia</measure>
    <time_frame>3 weeks after beginning of prophylaxis</time_frame>
    <safety_issue>No</safety_issue>
    <description>How many patients reached the ANC &gt; 0.5Ã—109/L more than 3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>3 weeks after beginning of prophylaxis</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>How many patients developed unexpected medical events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of drug and hospital-stay</measure>
    <time_frame>3 weeks after beginning of prophylaxis</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Neutropenia</condition>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>No prophylaxis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>piperacillin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>piperacillin/tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin</intervention_name>
    <description>4.0g q8h 3-5 days</description>
    <arm_group_label>piperacillin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin-tazobactam combination product</intervention_name>
    <description>4.5g q8h 3-5 days</description>
    <arm_group_label>piperacillin/tazobactam</arm_group_label>
    <other_name>Tazocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 13-65 years

          -  Received Autologous or Allogeneic hematopoietic stem cell transplantation.

          -  ECOG score 0-1.

          -  ICF is available.

        Exclusion Criteria:

          -  Allergic to any therapy drug.

          -  Documented infection before neutropenia.

          -  Renal dysfunction.

          -  Suffering from central nervous system or mental disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>wenrong huang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Employee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA general hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wenrong Huang, Doctor</last_name>
      <email>huangwr301@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 25, 2012</lastchanged_date>
  <firstreceived_date>July 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Wenrong Huang</investigator_full_name>
    <investigator_title>Associate director, Hematology, Chinese PLA General hospital</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Piperacillin-tazobactam combination product</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
